Enterprise partnerships BenchSci has established multi-year, large-scale collaborations with global biopharma leaders (Sanofi, Merck, Argenx) and ongoing expansions in preclinical drug discovery tools, signaling strong upsell potential for expanded license tiers, additional modules of EMET and ASCEND, and cross-sell opportunities within partnered organizations.

AI driven growth With significant funding and a mission to accelerate life-saving research using biomedical AI, BenchSci is expanding AI capabilities and toolsets for drug discovery, creating opportunities to position complementary analytics, data integration, and automation solutions that enhance existing platforms.

Global expansion Recent and ongoing collaborations across Europe and with major pharma players indicate a readiness to scale solutions internationally, suggesting sales plays focused on regional deployment, localization, and multi-site enterprise agreements.

Scaleable platform BenchSci’s ASCEND and EMET platforms cater to high-volume research environments, implying opportunities to upsell larger seat licenses, advanced analytics, and enterprise-grade security/compliance features for global research centers and CRO networks.

Remote-first culture Remote-first operations paired with strong recognition (Deloitte Tech Fast 50, Great Place to Work) support faster onboarding and distributed customer success, enabling scalable customer adoption strategies, virtual onboarding programs, and region-specific SDR outreach.